SGLT2 Inhibitors and External Genital Infection in Male Patients With Type 2 Diabetes
Main finding · MEGIResult — go to the resultHazard ratio 1.65 95% CI 1.59–1.71Authors' conclusion
These findings suggest that SGLT2Is are associated with a higher risk of MEGI in adult male patients with T2D, compared with GLP-1RAs. Clinicians should be cautious when prescribing SGLT2Is in male patients with T2D.
Study context
- Population
- Adult male patients with T2D newly treated 2009–2020, Taiwan's National Health Insurance Research Database
- Participants
- 239,757 patients
- Exposure
- SGLT2i vs GLP-1 RA
- SGLT2In = 224,360
- GLP-1RAn = 15,397reference
- Outcome
- MEGI
Methodological detailsactive comparator, propensity scores with inverse probability of treatment weighting
- Active comparator
- Propensity scores with inverse probability of treatment weighting
Main finding
As reported in the abstract
Hazard ratio
1.65
95% CI 1.59–1.71
SGLT2Ivs GLP-1RA
HR 1.65 (95% CI 1.59–1.71)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| MEGI, age <60 years | 2.04 (1.58–2.65) | |
| MEGI, eGFR of 60 mL/min/1.73 m² | 1.69 (1.34–2.15) | |
| MEGI, HbA1c below 7% | 3.22 (1.71–6.03) | |
| 0.10.31310Hazard ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
SGLT2 Inhibitors and External Genital Infection in Male Patients With Type 2 Diabetes. JAMA Netw Open. Published 2 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →